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Several of the active compounds in foods, poisons, drugs, and industrial chemicals may, by epigenetic mechanisms, increase
or decrease the risk of breast cancers. Enzymes that are involved in DNA methylation and histone modiﬁcations have been
shown to be altered in several types of breast and other cancers resulting in abnormal patterns of methylation and/or acetylation.
Hypermethylation at the CpG islands found in estrogen response element (ERE) promoters occurs in conjunction with ligand-
bonded alpha subunit estrogen receptor (Erα) dimers wherein the ligand ERα dimer complex acts as a transcription factor and
binds to the ERE promoter. Ligands could be 17-β-estradiol (E2), phytoestrogens, heterocyclic amines, and many other identiﬁed
food additives and heavy metals. The dimer recruits DNA methyltransferases which catalyze the transfer of methyl groups from
S-adenosyl-L-methionine (SAM) to 5 -cytosine on CpG islands. Other enzymes are recruited to the region by ligand-ERα dimers
which activate DNA demethylases to act simultaneously to increase gene expression of protooncogenes and growth-promoting
genes. Ligand-ERα dimers also recruit histone acetyltransferase to the ERE promoter region. Histone demethylases such as
JMJD2B and histone methyltransferases are enzymes which demethylate lysine residues on histones H3 and/or H4. This makes
the chromatin accessible for transcription factors and enzymes.
1.Introduction
Breast cancers are the most common malignancies and caus-
es of cancer deaths in women worldwide, consisting of ap-
proximately 18% of all female cancers. The incidence of
breast cancers is much higher in Western than in East-
ern countries [1] and geographical variation indicates a
signiﬁcant role of environmental factors in the risks for
breast cancers. The Japanese who migrate to Hawaii develop
the disease at similar rates as their native counterparts in
Hawaii within one or two generations [2]. Upon examining
the molecular mechanisms underlying the development and
progression of breast cancers, genetic mutations have been
an evident cause that has long been established. However,
epigenetic mechanisms are now becoming recognized as
signiﬁcant factors in the development of breast cancers.
Epigenetic mechanisms coordinate biological processes such
as X-chromosome inactivation, position eﬀect variegation,
genomic imprinting, RNA interference, and reprogramming
of the genome during diﬀerentiation and development
leading to gene silencing [3]. Defects in any of these func-
tions may cause human disorders including breast cancer.
Epigenetic malfunctions are manifested through aberrant
methylation and acetylation of genes and histones involved
in normal tissue development to activate or silence gene
expression. Consequently, abnormal tissue diﬀerentiation
and growth may result from the loss of crucial cell adhesion
proteins and overexcitation of estrogen receptor pathways.
Additionally, migration of abnormal cells is increased.
Angiogenesis which nourishes tumor growth and important
intracellular signal transduction networks such as those for
apoptosis,DNArepair,anddetoxiﬁcationareinvolved.Thus,
numerous molecular processes could go awry because of
epigeneticmalfunctions.Epigeneticmechanismsarestrongly
inﬂuenced by environmental factors such as the chemicals
in foods. The occurrences of such epigenetic processes,
therefore, suggest that individuals should ingest a balanced
diet that includes foods which are known to be protective
and supportive while avoiding or limiting exposures to the
known risk factors for breast cancers.2 Obstetrics and Gynecology International
2.EpigeneticMechanisms:
MethylationandAcetylation
2.1. DNA Methylation of CpG Islands and Methylation Im-
balance in Cancer Cells. CpG islands are short sequences
of genomic DNA with the length of 0.5 kilobase to several
kilobases [4] in which the frequency of the linear 5 -
CpG-3  sequence is higher than at other regions of the
gene, where “p” indicates the phosphodiester bond that
connects cytosine and guanine nucleotides [5]. Typical CpG
islands are unmethylated and are most commonly found in
5 -regulatory (promoter) regions of many “housekeeping”
genes (which are essential for general cell functions) and in
sometissue-speciﬁcgenes[6].Althoughasigniﬁcantportion
of CpG islands are in the 5 -untranslated regions and the
ﬁrst exon of genes, they are also found in the 3 -region and
within the body of genes. Atypical locations (referring to
exonic CpG islands that are not at promoters) are equally if
not more prone to methylation [7].
In breast cancers and in many other disease states,
hypermethylation of CpG islands results from overactivity
of DNA methyltransferases (DNMTs). DNMTs are the main
mediators of DNA methylation by catalyzing the transfer
of a methyl group from S-adenosyl-L-methionine (SAM)
onto the carbon on the 5 -position of CpG dinucleotides.
In humans, the primary DNMTs are DNMT1, DNMT3a,
and DNMT3b. DNMT1 is the most abundant and func-
tions to maintain the methylation pattern while the other
DNMTs serve as the mediators of de novo methylation
[8]. The consequence of hypermethylation of CpG islands
is (reversible) silencing of tumor suppressor genes. Such
hypermethylation-induced gene silencing is heritable, that
is, inherited by subsequent generations of cells undergoing
mitotic divisions. DNA methylation of gene coding regions
suppresses gene expression in normal cells [9]. However, in
cancercells,thereappearstobewidespreadhypomethylation
of the genomic DNA with hypermethylation localized at the
normally unmethylated promoter regions, thereby produc-
ing“methylationimbalance”[10].Methylationisalsoknown
to activate the human telomerase reverse transcriptase
(hTERT) gene [8], thereby promoting cell immortality in
some cancer cells. On the other hand, hypomethylation of
CpG islands has been shown to increase expression of some
cancer-promoting oncogenes [11].
Genomewidemethylationpatternsarethoughttobereli-
able indicators of environment-gene interactions. Whereas
histone methylation results in short-term inhibition of gene
expression,DNAmethylationattheCpGislandsofpromoter
regions generates long-term gene silencing and makes the
majority of chromatin inaccessible for transcription [12].
The methylation pattern is thought to be determined very
early in embryogenesis, at implantation [13]. CpG islands
appear to play unique roles in development and diﬀerentia-
tion. Although unmethylated CpG islands of gene promoter
regions mark sites where genes can be expressed, non-
CpG sequences at nonpromoter regions closely associated
with transcription start sites may be important for tissue-
speciﬁc dynamical de novo methylation [14]. Methylation
of such non-CpG sites has been implicated in somatic cell
reprogramming [12] like that which may occur in response
to the environment-gene interactions which promote the
development of breast and other cancers.
DNA methylation may serve as a marker of breast
tumor cell lineage restriction, thereby reﬂecting the cell type
from which a cancer originates and, perhaps, explaining the
correlations of histological heterogeneity and prognosis of
breast cancers with their DNA methylation proﬁles [15].
The expression of estrogen receptors in hormone-dependent
tumors has also been correlated with the clinical outcomes
of cancer patients [16]. The ﬁndings of a signiﬁcant num-
ber of hypermethylated genes suggest that the amount of
methylation of speciﬁc gene clusters may be correlated with
the presence of estrogen and progesterone receptors, tumor
relapse, and lymph node metastasis [17]. The expression
of six genes (RECK, SFRP2, UAP1L1, ACADL, ITR, and
UGT3A1) is reported to be signiﬁcantly correlated with
methylation and relapse-free survival; the RECK gene is
notable because of its association with the worst cancer
prognoses [17]. Moreover, global hypomethylation of breast
cancer cell DNA is reported to be associated with a novel
methylation pattern. The expression of genes within partially
methylated domains in normal breast cells is, paradoxically,
inhibited in cancer cells. Hypomethylation of DNA in these
regions is found to be associated with repressive chromatin
exhibitinganallelicpatternofmethylationwhereinoneallele
is DNA-methylated and the other allele contains the histone
modiﬁcations H3K9me3 or H3K27me3 [18].
2.2. Histone Modiﬁcations. Histone modiﬁcations are cata-
lyzed by several enzymes: Histone acetyltransferases (HATs),
histone deacetylases (HDACs), histone methyltransferases
(HMTs),andhistonedemethylases(HDMs).Histonemethy-
lation and acetylation to activate or deactivate genes depend
on which residue of the histone is modiﬁed. For exam-
ple, trimethylation of lysine 4 on histone H3 (H3K4me3)
activates gene transcription but on lysine 9 (H3K9me3)
and lysine 27 (H3K27me3) suppress, gene transcription.
Methylation of arginine is presumed to also activate tran-
scription. Histone acetylation at lysine residues located at
gene promoter regions may activate genes by relaxing and
opening the chromatin, thereby providing access to the DNA
by transcriptional enzymes and other factors [8].
3.Estrogens andEpigenetic Mechanismsin
Breast Cancers
3.1. The Role of Estrogens and Estrogen Receptors (ERs). Es-
trogens have been recognized as the major hormones stim-
ulating the growth and development of breast cancers. The
activities of estrogens are mediated by the two main isoforms
of intracellular estrogen receptors (ERs): ERαandERβ which
are encoded by the genes ESR1 and ESR2, respectively. These
cytoplasm/nuclear ERs have structural characteristics of the
nuclear receptor superfamily and they can form homo- or
heterodimers when activated by an eﬀective ligand. These
dimers can function as transcription factors to regulate gene
expression. There are also some ERs located in the plasmaObstetrics and Gynecology International 3
and/or organelle membranes associated with G-proteins,
tyrosine kinases (e.g., EGFR and IGF-1), and nonreceptor
tyrosinekinases.TheseERsareinvolvedinsignalingcascades
to increase second messengers and activate other proteins
and kinases [19]. Thus, the activities of ERs involve both
genomic pathways to activate or repress transcription, as
well as nongenomic pathways via intracellular signaling to
controlcellcycleprogression[20].Non-nuclearER-activated
mechanisms are reported to have the capacity to induce
proliferation of endothelial cells but not of endometrial or
breast cancer cells [21].
ERα-mediated transcription appears to increase the risk
of breast cancers [22]. Endogenous estrogens synthesized by
various body tissues and exogenous estrogens ingested in
foods are the most apparent causes of such breast cancers.
The primary estrogen in postmenopausal women is estrone
(E1) whereas about 70% of the endogenous estrogens is
comprisedof17-β-estradiol(E2),althoughE1andE2appear
to be equally distributed in the sera of premenopausal
women [23]. E1 is converted to E2 by catabolism in the liver
and 17-β hydroxysteroid dehydrogenase activity is reported
to be higher in breast tumors than in normal breast tissues
[24]. A higher serum level of E2 appears to promote the
development of breast cancers in postmenopausal women
[24]. However, a clear relationship between serum levels
of E1 or E2 and risks for breast cancers in premenopausal
women is lacking [25]. These ﬁndings suggest the hypothesis
that strategies which block hepatic conversion of E1 to E2
may decrease the risk of breast cancers in postmenopausal
women.
The main sources of biosynthetic estrogens include
the reproductive organs such as mammary and adipose
tissues. Several studies have shown that postmenopausal
obese women (above age 55) have an increased risk of
breast cancers because of increased estrogen production
from aromatization of androgens in peripheral fat tissues
[26]. Also, the production of sex hormone-binding globulin
a m o n go b e s ew o m e ni sd e c r e a s e d ,h e n c e ,p o s s i b l yr a i s i n g
the level of unbound (free) estrogen to target tissues [26].
Furthermore, Suzuki et al. [26] have shown that the risk
of developing estrogen receptor-positive and progesterone
receptor-positive (ER+ and PR+) breast cancers is increased
in individuals possessing a relatively high body weight.
However, this study showed an inverse correlation between
body weight and the development of ER+ PR− and ER−
PR− tumors. A signiﬁcant diﬀerence between PR+ and PR−
tumorsinrelationtobodyweight(i.e.,PR+andPR−tumors
among obese patients with BMI > 30kg/m2 is reported to
be high compared to the proportion among underweight
patients with BMI < 18.5kg/m2. These ﬁndings suggest
the possibility that estrogen, via ER stimulation, gives rise
to PR+ tumors [27]. In fact, it has long been established
by in vitro studies that estrogen regulates the expression
of PR via ER in breast cancer cells [28]. These results
support the epidemiological ﬁndings that postmenopausal
status and obesity synergistically increase the risk of breast
cancers and that obesity alone confers signiﬁcant risk for
breast cancers.Although some studies have shown that obese
postmenopausal women have as much as a 50% greater
risk for breast cancers than nonobese women, being over-
weight/obese is also associated with signiﬁcantly increased
risksofrecurrencesanddeathsfrombreastcancersregardless
of menopausal status [29].
3.2. Epigenetic Suppression of ERα in Breast Cancers. ERα is
expressed in about 75% of diagnosed breast tumors (ERα
p o s i t i v e )a n dw o m e nw i t hs u c ht u m o r sa p p e a rt oh a v ea
better prognosis because of their responsiveness to hormone
treatment [30]. On the other hand, women having breast
tumors without ERα expression (ERα negative) are shown to
have poorer prognosis and greater malignancy [31]. Several
mechanisms have been proposed to explain the cause of
suppressing ERα expression seen in ER-negative tumors. For
example, estrogen withdrawal, hypoxia, overexpression of
epidermal growth factor receptor (EGFR) or erythroblastic
leukemia viral oncogene homolog 2 (ERBB2), and hyperac-
tivation of mitogen-activated protein kinases (MAPKs) have
been suggested [31].
Another mechanism for suppressing the expression of
ERα is epigenetic silencing via aberrant methylation of the
ERα promoter. The loss of expression of ERα and/or E-
cad (cell-cell adhesion molecule) genes appears to result
from aberrant methylation of CpG islands [31]. ERα and
E-cad both play important roles in maintaining the normal
diﬀerentiated state of the mammary gland epithelium. Nei-
ther gene is methylated in normal breast epithelia; however,
methylation has been observed in all tumor stages with
greaterincidencesduringprogressionfromductalcarcinoma
in situ (DCIS) to metastatic tumors [31]. These results
suggest that epigenetic silencing of the ERα and E-cad genes
may occur prior to invasion and may, therefore, increase as
cells acquire invasiveness, and metastatic potential. Greater
frequencyofcoincidentmethylationofCpGislandsisaresult
of the accumulation of epigenetic “hits” that contribute to
gene silencing. Consequently, ERα loss during breast cancer
progression is associated with poor histological diﬀerentia-
tion,highgrowthfraction,andadverseclinicaloutcomesand
may represent a key mechanism facilitating hormone resis-
tance [31]. Similarly, loss of E-cad expression is associated
with loss of diﬀerentiation, increased invasiveness and high
metastatic potential which decreases patient survival. Loss of
the ERα and E-cad expressions which support normal cell
g r o w t hc o u l db ea ne v o l u t i o n a r ya d a p t i o nt os t o pt u m o r
growth; however, these adaptations may not have advanced
to the stage of stopping growth before the cancer cells have
established their invasive and metastatic potential.
ER suppression by microRNAs (miRNAs) has also been
shown. MiRNAs are small noncoding RNAs that suppress
gene expression posttranscriptionally by base pairing to 3 -
untranslated regions (3 UTR) of target mRNAs. A study
by Di Leva et al. [30] has demonstrated a loop regulation
between miR-221-222 and ERα.E R α appears to bind to
miR-221-222 and recruit the corepressors NCoR and SMRT
to the miR-221-222 promoter region and, thereby, reduce
their expression. Overexpression of miR-221 and -222 in
ERα-positive breast cancer tissues results in ERα suppression
at the post-transcriptional level and also suppresses the
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CDKN1C, BIM, PTEN, TIMP3, DNA-damage-inducible
transcript 4, and FOXO3. Consequently, miR-221-222 pro-
motes high proliferation and estrogen-independent growth.
Interestingly, miRNA expression is regulated by ERα and
these ﬁndings suggest that the activity of this regulatory loop
may confer proliferative advantage and migratory activity
to breast cancer cells and promote the transition from ER-
positive to ER-negative tumors [30].
3.3. Estrogens and Histone Demethylation: Modifying Histones
via Demethylation by ERα and JMJD2B. JMJD2B is a histone
lysine-speciﬁc demethylase and enrichment of H3K9me3
distal to the ER binding site functions as a repressive
mark of transcription. Upon activation of E2, a process
that is dependent on JMJD2B, the methylation level of
H3K9me3 may be decreased [32]. This mechanism for
JMJD2B to decrease the level of H3K9me3 may enhance
thetranscriptionalactivationofoncogenesandantiapoptotic
genes. The mechanism of E2 and JMJD2B is as follows: E2
induces JMJD2B expression in an ERα-dependent manner
and available JMJD2B is then recruited to ERα target
sites, interacts with ERα and SWI/SNF, and demethylates
H3K9me3 to facilitate transcription of ER responsive genes
including MYB, MYC, CCND1. Knockdown of JMJD2B
impairs E2-ERα cell proliferation and tumor formation, and
its deletion from mammary epithelial cells produces delayed
mammary gland development in mice [32]. These ﬁndings
suggest that JMJD2B is necessary for the full extent of ERα
transcriptional activity.
3.4. Estrogens and Histone Acetylation: E2-ERα Dimers and
HATs Modify Histones by Acetylation. E2 works by binding
to the ERα monomer and releasing chaperone proteins that
change the conformation of the ER. Binding of E2 causes
ERα monomers to dimerize and enter the nucleus to act
as transcription factors [33]. ERs work in conjunction with
HATs and the histone lysine-speciﬁc demethylase JMJD2B
w h i c ha c t sa sac o a c t i v a t o rt oo p e nt h ec h r o m a t i nf o rt r a n -
scription. E2-ERα dimers recruit ATP-dependent chromatin
remodeling complexes (SWI/SNF) and histone modifying
enzymes to estrogen-responsive promoters [20]. This gives
rise to an increase in breast cell divisions which have the
potential to promote tumor growth and increase replicating
errors in cancer-related genes. Histone modifying enzymes
include the HATs, namely, p160, CBP, p300, and pCAF,
which are recruited sequentially. Certain HATs also work to
facilitate binding to RNA polymerase II and priming the
promoter for multiple rounds of transcription [20].
In addition to the endogenous estrogen E2, various
sources of xenoestrogenic compounds such as birth control
pills, estrogen replacement therapy, and phytoestrogens are
known to activate the ERα monomer. These phytoestrogenic
ligands, which are known to promote cancers, seem to work
by binding to the ERα monomer whereas those that inhibit
cancers appear to do so by binding to the ERβ monomer
[34]. ERβ is reported to have opposite eﬀects to that of ERα,
butthemechanismsremainunclear[34].Theseobservations
imply that cancer tumor growth promotion and inhibition
by phytoestrogens may depend on the relative expressions of
ERα and/or ERβ, as well as of the homo- and heterodimers
ERαα,E R ββ,a n dE R αβ in speciﬁc tissue types. These dimers
may be diﬀerentially expressed in normal breast tissue and
breast cancer cells [35]. Because phytoestrogens appear to
have greater aﬃnity for the ERβ than the ERα monomer,
inhibitionoftumorgrowthmaybethepredominanteﬀectof
phytoestrogens in breast cancers. However, the role of ERβ is
notaswellstudiedasthatofERαanditsmechanismofaction
needs further investigation.
4.FoodIngredientsandEpigeneticMechanisms
inBreast Cancers:Folate/Methionine,
Betacarotene/Arachidonic Acid, Heterocyclic
AminesPhIPandFoodAdditiveBHA
4.1. Folate, Methionine and DNA Methylation. Because DNA
methylation requires methyl group donors such as SAM, it
is necessary to have a source of methyl groups. Two main
sources of methyl groups found in foods are methionine
and folate. Methionine is an essential amino acid found in
poultry, ﬁsh, and dairy products while folate is an essential
nutrient found in fruits and vegetables [36]. Numerous
studies suggest that DNA methylation may be inﬂuenced by
diet. Diets low in methionine and folate or high in methyl
group antagonists such as ethanol result in aberrant methy-
lation patterns of DNA, including global hypomethylation
and methylation of normally unmethylated CpG sites [36].
Global genomic hypomethylation can result from decreased
levels of SAM whereas hypermethylation of unmethylated
CPG sites can be produced by increases in the activities of
DMNTs [37]. In a study of 304 African-American women
diagnosed with breast cancers during 1995–1998 living in
Tennessee, signiﬁcant positive correlations were reported for
low methionine intake with unknown methylation status
of ERα-positive tumors and high ethanol consumption
with unmethylated ERα. On the other hand, there was
no signiﬁcant data showing a correlation between methyl-
deﬁcient diets and methylation of the ERα gene [36].
These ﬁndings suggest that methyl-deﬁcient diets may result
in hypomethylation of ERα genes and, thus, give rise to
ERα-negative tumors. Another study demonstrated similar
results, showing a trend toward decreased methylation with
increasing ethanol intake and a trend toward increased
methylation with increasing dietary folate [38]. Because
ethanol inhibits the absorption of folate in the intestine and
interfereswithhepaticreleaseoffolate,theseﬁndingssuggest
that the primary carcinogenic mechanism of alcohol intake
may be interference with epigenetic regulation through
disruption of one-carbon metabolism [38]. It, therefore,
seems advisable to insure adequate folate and methionine
intake and to limit ingestion of alcohol to decrease the risks
for breast cancers.
4.2. Beta-Carotene, Arachidonic Acid, and DNA Hypomethy-
lation: Promotion of Angiogenesis by Upregulating Tyrosine
Kinase VEGFR-2 Receptor (KDR) Expression Via Demethy-
lation of DNA CpG Islands in the KDR Gene. Angiogenesis
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ﬁrst antiangiogenesis drug approved by the US Food and
Drug Administration (FDA) in 2008 for metastatic breast
cancers but recently found by an FDA panel to be ineﬀective
at increasing the survival of breast cancer patients [39].
BevacizumabinhibitsproductionandreleaseofVEGF-A,the
most potent paracrine stimulator of angiogenesis [29]a n d
activator of the tyrosine kinase VEGFR-2 receptor (KDR), a
coactivator of angiogenesis. Beta-carotene (BC) is reported
to be proangiogenic [40]. Kiec-Wilk et al. [41]h a v er e p o r t e d
that BC, present in brightly pigmented red, orange, and
yellow fruits and vegetables, as well as arachidonic acid
(AA), an omega-6 fatty acid present in vegetable oils, may
promote angiogenesis by increasing expression of the KDR
in endothelial cells. Moreover, it is reported that incubation
of endothelial cells with physiological concentrations of
BC (3–10μM) or AA (3μM) decreases the global DNA
methylation of endothelial cells, as well as methylation
of the KDR promoter region. These ﬁndings suggest that
hypomethylation of the KDR promoter region is a likely
mechanism for upregulation of KDRs in endothelial cells by
BCandAA.KDR,beinganimportantproteininchemotaxis,
diﬀerentiation, and angiogenesis [41], suggests roles for
BC and AA in breast cancers. The omega-3 fatty acids
found in animal meats like chicken and egg yolks promote
cellular uptake of BC and AA. Thus, avoidance of high-fat
diets appears to be a reasonable strategy for inhibiting the
angiogenesis associated with breast cancers. Moreover, BC
is known to be stored in adipose tissue, thereby providing
a plausible explanation for the predilection for breast cancers
in obese women. It is noteworthy that, in ovariectomized
mice, tumor VEGF levels in blood and adipose tissues have
been reported to be higher during a period of high-fat
compared to a period of low-fat dietary treatments. This
ﬁnding suggests that both high body fat content and high
fat diets may have the potential to increase VEGF levels, the
substrates for KDRs and angiogenesis.
4.3. PhIP in Cooked Meat: PhIP Acts Like E2 to Induce Gene
ExpressionviaanERαMechanism. PhIPisaphenylimidazole
pyridine and one of three mutagenic and carcinogenic
heterocyclic amines (HAs) produced during the cooking of
meats such as beef, pork, and chicken. The concentration
of PhIP in these meats increases with the degree of heat
applied when cooking; for example, burnt meat has the
highest concentration of PhIP but even small concentrations
of PhIP in cooked meats are thought to have physiological
eﬀects. Exposure to PhIP has been shown to increase cell
proliferation in mammary gland terminal end buds, sug-
gesting that PhIP promotes tumorigenesis [42]. A relatively
low level of PhIP in breast milk has been demonstrated to
exertestrogenicandmitogeniceﬀectsinhumansviaaMAPK
pathway [43]. PhIP appears to bind, speciﬁcally albeit at a
lower aﬃnity than E2, to the ERα-ligand binding domain
and, therefore, competes with E2 at its binding site, thereby
suggesting an epigenetic mechanism for PhIP, akin to that
of E2, in breast cancers [44]. Interestingly, the PhIP phase I
metabolites, N2-OH-PhIP, MeIQx, and IFP, are reported to
inhibit the activation of ERα. Treatment of MCF-7 breast
cancer cells with PhIP and these metabolites signiﬁcantly
inhibits ERα transcription activity at a much lower level
than treating with PhIP alone. Hence, although PhIP is
carcinogenic, these PhIP metabolites are anti-estrogenic
[42]. This suggests that dietary constituents have both
activatingandinhibitingeﬀectsonhormone-sensitivetissues
such as some breast cancers and the risks and development
of breast cancers may result either from a defect in the
mechanismsformetabolizingPhIPorfromoverloadofPhIP.
4.4. Food Additives: Bisphenol (Antioxidant t-Butylhydrox-
yanisole, BHA) Is Estrogenic. More than 90 types of chemi-
cals and food additives exert estrogenic activity to stimulate
cell growth [45]. Bisphenol A, also known as antioxidant
t-butylhydroxyanisole (BHA), is the most extensively used
antioxidant in the food industry. BHA is used in fats and
oils, fat-containing foods, confectionaries, essential oils, and
food-coating materials such as metal cans and waxes. BHA is
also often found in polycarbonate plastics (recycle symbol 7)
like in some sports drink and infant nursing bottles. BHA is
an environmental estrogen because it is a synthetic chemical
theactionsofwhicharesimilartoestrogen.Morespeciﬁcally,
BHA is considered as an epigenetic carcinogen because it
causes cell proliferation via epigenetic events [46]. In a study
testing the two food additives BHA and o-phenyl phenol
(OPP),theassayofERcompetitiveinvitrobindingtohuman
ERα and ERβ showed that BHA had the capacity to compete
with E2. On the other hand, the capacity of OPP was too
small to calculate. However, both BHA and OPP induced
ad e c r e a s ei ng e n ee x p r e s s i o no fE R α and an increase in
that of PRs in a time-dependent manner. These eﬀects were
similar to that of E2, although much higher concentrations
were required for BHA and OPP than E2 [45]. In the case
of BHA, the danger is that it is widely used. Wear and tear,
harsh detergent, and heat can cause BHA to leach out of
bottles into the ﬂuid contained therein. Studies conducted
in Europe and Japan have reported that BHA can migrate
from plastic polyvinyl chloride stretch plastic wraps to food.
BHA has also been detected in recycled cardboard (source
probably from thermal fax paper which contains BHA) and
in“virgin”paperproducts[47,48].Itis,therefore,important
tousestainlesssteelbottlesorplasticwithoutBHAandavoid
reusing or heating BHA-containing products. These ﬁndings
suggest that constant exposure to BHA containing products
and excessive food additives could result in accumulation in
the body to increase the risk of breast cancers.
5.HeavyMetals andTheirEpigenetic
MechanismsinBreast Cancers
5.1. Aluminum and Cadmium. Aluminum (Al) is a heavy
metal element that is widely used in foods, cosmetics, and
other products of human consumption. Al is shown to be
carcinogenic by a mechanism akin to that of estrogens;
hence, Al is known as a “metalloestrogen.” Al binds to ERs
and triggers the expression of genes found on estrogen-
responsive elements (EREs). There is evidence that certain
salts of Al such as those found in antiperspirants can remain
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periods if not washed well, thereby providing the potential
for continuous exposure to Al and enhancement of the risks
for breast cancers [11]. Cadmium (Cd) is a similar metalloe-
strogen with a mechanism of action that involves inducing
the expression of heat shock proteins, Hsp 22 and Hsp
27. Treatment of MCF-7 human breast cancer cells, which
express ERα with either E2 or with Cd appears to increase
the expressions of Hsp 22 and Hsp 27 [11]. These heat shock
proteins are known to form homo- or heterodimers, and
high-molecular-weight complexes are shown to be present in
breast cancer cells; however, the exact structure and function
of these dimmers remain unclear [49]. According to the
United States Department of Labor, there are numerous
occupations and work environments that expose workers
to toxic heavy metals [50]. Cd is an extremely toxic
metalcommonlyfoundinindustrialworkplaces,particularly
where ores are processed or smelted, thereby putting a large
group of metal workers at risk for breast cancers, perhaps,
by epigenetic mechanisms involving ERα responsiveness to
heat shock proteins. Several deaths from acute exposure have
occurredamongwelderswhohaveunsuspectinglyweldedon
Cd-containing alloys or with silver solders.
5.2. Arsenic, Selenium, Chromium, and Nickel. Certain heavy
metals have not been shown to play a role in breast
cancers but have been demonstrated to act on the same
regulatoryenzymespreviouslyshowntoplayimportantroles
in breast cancers. Arsenic (As) competes with DNMT for
SAM, potentially limiting the availability of SAM to be used
by DNMT to catalyze methylation of CpG islands. Such
limitation could result in hypomethylation and reactivation
of (silenced) tumor suppressor genes. Common sources
of exposure to higher-than-average levels of As include
occupations near or in hazardous waste sites and areas with
highlevelsnaturallyoccurringinsoil,rocks,andwater.Thus,
individuals engaged in a wide variety of occupations such
as miners, construction, and waste workers are at risk for
breast cancers. Similarly, for detoxiﬁcation, selenium (Se)
also requires SAM. Se may, therefore, compete with As and
DNMT, thereby also contributing to DNA hypomethylation
[11]. Chromium (Cr) is another heavy metal found in raw
onion, romaine lettuce, beef, chicken, liver, and many other
foods.Crisanessentialmineralandhasbeenshown,atsome
dosages associated with over-the-counter supplementation,
to promote health by supporting normal cholesterol, blood
glucose, and insulin levels [51]. However, Cr is also reported
to be carcinogenic at high concentrations such as those
which may occur from over-supplementation. Cr recruits
HDAC1 and DNMT1 to promoters such as the CYP1A1
promoter and forms a complex that recruits binding protein
1 and inhibits the expression of CYP1A1 [11]. CYP1A1 is
an important detoxiﬁer that metabolizes carcinogens such as
polycyclic hydrocarbons (PHs) and polycyclic amines (PAs)
[11]. PAs such as PhIP can increase the risk of breast cancers
by binding to and activating ERα, and the PhIP metabolites
N2-OH-PhIP, MeIQx, and IFP inhibit the activation of ERα
[42]. It, therefore, appears that by decreasing the expression
of CYP1A1, Cr may limit the metabolism of PAs, cause PAs
to accumulate, induce binding of PAs to ERα, and either
activate or block activation of ERα, depending on the PA
metabolite proﬁle. Calcium chromate, chromium trioxide,
lead chromate, strontium chromate, and zinc chromate
are human workplace carcinogens known to increase the
incidence of lung cancers among workers in industries that
produce chromate and manufacture pigments containing
chromate [50]. The heavy metal element Nickel (Ni) seems
to induce carcinogenic eﬀects by inducing hypermethylation
of H3K9, inhibiting DNMT and inhibiting histone H2A,
H2B,H3,andH4acetylationwhichsilencetumorsuppressor
genes [11]. Ni appears to bind diﬀerentially to various
parts of histones. Ni binding to histone H4 is reported to
inhibit histone lysine acetylation, thereby inducing DNA
hypermethylation [11].
6. Anticancer Effects of Foods
Several of the active compounds in foods work epigenetically
to decrease the risk of breast cancers [8]. Enzymes involved
in DNA methylation and histone modiﬁcations have been
shown to be altered in several types of cancers resulting in
abnormal patterns of methylation and/or acetylation. Many
cancer drugs work by altering the activity and expression of
these enzymes. Interestingly, some components of natural
foods have similar actions on these enzymes and therefore
produce anticancer eﬀects.
6.1. Tea Polyphenols, EGCG. Epigallocatechin-3-gallate
(EGCG) is a polyphenol in teas that humans ingest. EGCG
is reported to block DNMT1-induced methylation of the
CpG islands present in many genes, including tumor sup-
pressor genes, in a concentration-dependent manner [52].
EGCG seems to directly inhibit, by hydrogen bonding,
the key nucleotide cytosine from entering the DMNT1
active site, thereby, eﬀectively preventing DNA methylation.
Consequently, EGCG reactivates tumor suppressor genes
and inhibits tumor promoter genes such as hTERT, which
increases with hypermethylation [8]. Such inhibition of
hTERT is signiﬁcant because of reports of higher levels of
hTERT in breast cancers than in other cancers and of a
positive correlation of hTERT with telomerase activity, a key
enzyme in cell immortalization [53].
6.2. Genistein: An Isoﬂavone Found in Lupin, Kudzu, Pso-
ralea, Fava, and Soybeans. Genistein is an antioxidant and
phytoestrogen, known to inhibit DNMT1/3a/3b and to
contribute to inactivating histone H3K9me3 and repressing
hTERT expression in human breast cancer cells [8]. The
estrogenic eﬀects of genistein are thought to be mediated
by an ERβ pathway [34]. Cappelletti et al. [34] have shown
that treatment of hormone-sensitive (T47D) and hormone-
independent (BT20) cell lines with genistein results in
increased expression of ERβ2 mRNA, modulated by the
ERβ2 isoform, thereby inhibiting estrogen-promoted cell
growth. These ﬁndings suggest that the potential beneﬁts
of genistein as a chemotherapeutic or prevention agent
for breast cancers are likely mediated by an epigenetic
mechanism related to expression of ERβ2 mRNA. Concerns
have been raised about the overall beneﬁts of soy productsObstetrics and Gynecology International 7
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Figure 1: Five mechanisms for epigenetic alterations in breast cancers. Each alteration involves many enzymes but the main players to cause
methylation or acetylation are shown by arrows. These are not separate mechanisms and the enzymes do not act alone. Several enzymes act
at a promoter simultaneously. (1) Hypermethylation at the CpG islands found in estrogen response element (ERE) promoters. When ligand-
(L-) bonded ERα dimerizes, the complex (L-ERα dimer) acts as transcription factor and binds to the ERE promoter. Ligands could be E2,
phytoestrogen, PhIP, and so forth. The dimer may recruit DNMTs which catalyze the transfer of methyl groups from SAM to 5 -cytosine on
CpG islands. (2) Other enzymes could be recruited to the region by L-ERαdimers which activate DNA demethylases to act simultaneously to
increase gene expression of protooncogenes and genes involved in cell growth. (3) L-ERα dimer may also recruit SWI/SNF and HATs to the
ERE promoter region. HATs include p160, CBP, p300, pCAF. (4) Histone demethylases such as JMJD2B and (5) histone methyltransferases
(HMTs) are enzymes which acetylate lysine residues on H3 and or H4 to open up the chromatin for other transcription factors and enzymes.
Enzymes/cofactors:DNAmethyltransferases(DNMTs),s-adenosylmethionine(SAM),histoneacetyltransferases(HATs),histonemethylases
(HDM) JMJD2B, histone methyltransferases (HMTs), and DNA demethylases (member of MBD, methyl CpG-binding domain, family
proteins).
because of the estrogenic and antiestrogenic properties of
theirisoﬂavones.Genistein’santicancerandprocancereﬀects
have been attributed to its biphasic properties [54]. The
estrogenic eﬀect has been observed when administration of
genistein at a low dose has induced growth of ER-positive
breast cancer cells [55]. Genistein binds to ERs and inhibits
cytochrome P450 CYP1A1 which, in turn, increases the
production and release of E2 [56]. Studies have produced an
anti-estrogenic eﬀect of genistein by inhibiting the enzyme
17β-hydroxysteroid oxidoreductase type 1 (HSOR-1) that is
necessaryforE2secretionfromtheovariesinpremenopausal
women. Genistein may also be essential for the reduction of
E1 to E2 in adipose and other tissues [55]. Thus, the pro-
and anti-cancer eﬀects of genistein appear to depend on the
eﬀects of genistein on the production of estrogens.
In intact mice fed estrogen, genistein appears to produce
tumor growth inhibition [54]. Studies have also shown
that isoﬂavone supplements do not aﬀect breast tissue
density in premenopausal women but may decrease breast
tissue density in postmenopausal women [61]. Genistein is8 Obstetrics and Gynecology International
also reported to decrease cell proliferation and to induce
apoptosis, prevent DNA mutation, and inhibit angiogenesis
in breast cancer cells [8]. These novel ﬁndings on the
epigenetic mechanisms of genistein may help explain the
discrepancy of breast cancer risk in Western and Eastern
countries and the changes in the risk among Asians and
Asian-Americans. Epidemiological studies have indicated
that about one in eight women in the United States is
at risk for developing breast cancers while the risk is
ﬁvefold less in women in Japan and China [55]. Among
Chinese- and Japanese-Americans, the incidence of breast
cancer was found to be about 50% lower in Asian-born
women and 25% lower in US-born women than in US-
born Caucasians [57] .F u r t h e r m o r e ,m i g r a n ts t u d i e sh a v e
shown that Asian women who immigrated to the USA
and adopted a Western lifestyle developed a risk for breast
cancers comparable to that of Caucasian women within two
generations [58]. These studies suggest that environmental
factors may play a more signiﬁcant role than genetic factors
in breast cancer risk diﬀerence between Asian and Caucasian
women. An important environmental factor is soy product
consumption, which is widely ingested in Asian countries,
where the incidence of breast cancers is substantially lower
thaninWesterncountries[59,60].Interestingly,reportshave
indicated that Asian women living in Asia have up to 40%
lower serum estrogen levels than Caucasian women living
in the USA or Britain [55]. This could be attributed to the
factthat the consumption of phytoestrogens, particularly soy
products, is higher in Asia than in Western countries [59–
61]. A more speciﬁc study performed by Yamamoto et al.
[62] looked at various soy products commonly consumed in
Japan and breast cancer risk. This population-based cohort
study showed that the consumption of miso soup and
isoﬂavones, but not of soyfoods, was inversely associated
with the risk of breast cancers. Furthermore, this association
did not change substantially after adjustment for potential
confounders, including reproductive history, family history,
smoking, and other dietary factors. These correlations were
observed in premenopausal women but were reported to be
even stronger in postmenopausal women [62].
6.3.Sulforaphane:AnIsothiocyanateRichinBroccoli,Cabbage,
and Kale. Like genistein, sulforaphane (SFN) also inhibits
DNMTs in both MCF-7 and MDA-MB-231 breast cancer
cells. This inhibition of DNMTs is reported to induce site-
speciﬁc CpG demethylation of the ﬁrst exon of the hTERT
gene resulting in both dose- and time-dependent repression
of gene transcription [8].
7. Conclusions
Five mechanisms for epigenetic alterations in breast cancers
are summarized in Figure 1. Each alteration involves many
enzymes inducing methylation or acetylation which are not
separate mechanisms and the enzymes do not act alone. Sev-
eralenzymesactatapromotersimultaneouslysuchashyper-
methylation at the CpG islands found in estrogen response
element (ERE) promoters. When ligand- (L-) bonded ERα
dimerizes, the L-ERα dimer complexes act as transcription
factors and bind to the ERE promoters. Ligands could be E2,
phytoestrogen, PhIP, and so forth. The dimer may recruit
DNMTs which catalyze the transfer of methyl groups from
SAM to 5 -cytosine on CpG islands. Other enzymes could
be recruited to the region by L-ERα dimers which activate
DNA demethylases to act simultaneously to increase gene
expression of proto-oncogenes and genes involved in cell
growth. L-ERα dimers may also recruit SWI/SNF and HATs
to the ERE promoter region. Histone demethylases such as
JMJD2B and histone methyltransferases HMTs are enzymes
which demethylate histones, for example, lysine residues on
histones H3 and/or H4 to make the chromatin accessible to
transcription factors and enzymes.
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